ArticleFrontiers in immunology2019
Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study.
Abstract readMulticenter Study
In one paragraph
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment.Diagnostics (Basel, Switzerland) · 2026Article
- Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.Medicines (Basel, Switzerland) · 2024Review
- Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.Journal of clinical medicine · 2024Review
- Testing for the lupus anticoagulant: the good, the bad, and the ugly.Research and practice in thrombosis and haemostasis · 2024Article
- Type I interferon pathway activation across the antiphospholipid syndrome spectrum: associations with disease subsets and systemic antiphospholipid syndrome presentation.Frontiers in immunology · 2024Article
- Case Report:Frontiers in pediatrics · 2024Article
- An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus.Biomolecules · 2023Review
- COVID-19 and the antiphospholipid syndrome.Autoimmunity reviews · 2022Review
- A multi-laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network.International journal of laboratory hematology · 2022Article
- Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.International journal of molecular sciences · 2022Review
- An Update on Antiphospholipid Syndrome.Current rheumatology reports · 2022Review
- Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.Frontiers in immunology · 2022Observational
- Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies.Immunologic research · 2021Article
- Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository.The Journal of rheumatology · 2021Article
- Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study.Frontiers in medicine · 2021Article
- Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One.Frontiers in immunology · 2021Review
- Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk.Frontiers in immunology · 2021Article
- Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort.Frontiers in immunology · 2021Article
- Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke.Frontiers in cardiovascular medicine · 2021Article
- Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies.Biomedicines · 2020Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Savino SciasciaCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Massimo RadinCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Irene CecchiCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Elena RubiniCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Anna ScottaCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Roberta RollaAOU Clinical Chemistry Laboratory, "Maggiore della Carità" University Hospital, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Barbara MontaruliAO Ordine Mauriziano, Turin, Italy.
Patrizia PergoliniAOU Clinical Chemistry Laboratory, "Maggiore della Carità" University Hospital, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Giulio MengozziDepartment of Clinical Biochemistry, AOU Cittá della Salute e della Scienza, Turin, Italy.
Emanuela MucciniDepartment of Clinical Biochemistry, AOU Cittá della Salute e della Scienza, Turin, Italy.
Simone BaldovinoCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Michela FerroNephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Antonella VaccarinoHematology Division, and S. Giovanni Bosco Hospital, Turin, Italy.
Michael MahlerInova Diagnostics, Research and Development, San Diego, CA, United States.
Elisa MenegattiDepartment of Clinical and Biological Sciences, School of Specialization of Clinical Pathology, University of Turin, Turin, Italy.
Dario RoccatelloCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAntibodies, AntiphospholipidAntiphospholipid SyndromeAutoantibodiesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin IsotypesLupus Coagulation InhibitorMaleMiddle AgedProthrombinReproducibility of ResultsAntibodies, AntiphospholipidAutoantibodiesImmunoglobulin IsotypesLupus Coagulation InhibitorProthrombinAntiphospholipid Antibodiesantiphosphospholipid syndromeaPS/PTdiagnostic performancelaboratoryLupus Anticoagulantreliabilitythrombosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.